Related Experiment Video
Updated: Jan 21, 2026

Immunoglobulin G N-Glycan Analysis by Ultra-Performance Liquid Chromatography
Published on: January 18, 2020
Clinical Utility of Highly Purified 10% Liquid Intravenous Immunoglobulin in Kawasaki Disease
Takuya Oda1, Hazumu Nagata2, Yasutaka Nakashima1
1Department of Pediatrics, Japanese Red Cross Fukuoka Hospital, Fukuoka, Japan.
Abstract:
Compared with a 5% intravenous immunoglobulin, a 10% intravenous immunoglobulin as the first-line treatment of Kawasaki disease significantly reduced the fever duration (10 vs 13 hours, P = .022) among the responders, and the interval to adjunctive therapy for nonresponders (47 vs 49 hours, P = .035). There were no severe adverse events.
More Related Videos
Related Concept Videos
Local Anesthetics: Clinical Application as Intravenous Regional Anesthesia
One of the advantages of...
Chronic Kidney Disease II: Clinical Manifestations
Gastroesophageal Reflux Disease II: Clinical Features and Management
Clinical Manifestations
GERD presents itself in a multitude of ways, with symptoms varying from person to person. The hallmark symptoms are...
Coronary Artery Disease III: Clinical Manifestations
Rheumatic Heart Disease II: Clinical Manifestations and Diagnostic Studies
Peripheral Arterial Disease II: Clinical Manifestations and Diagnostic Evaluation

